External Scientific Advisory Board

Profiles, External Scientific Advisory Board

Dr. Victor Dzau (Chair)

Victor J. Dzau is the President of the U.S. National Academy of Medicine (NAM). In addition, he serves as Vice Chair of the U.S. National Research Council. He is Chancellor Emeritus and James B. Duke Professor of Medicine at Duke University and the past President and CEO of the Duke University Health System. Previously, Dr. Dzau was the Hershey Professor of Theory and Practice of Medicine and Chairman of Medicine at Harvard Medical School’s Brigham and Women’s Hospital, as well as Bloomfield Professor and Chairman of the Department of Medicine at Stanford University. Read more
 

Dr. Alan Bernstein

Alan Bernstein is President and CEO of CIFAR, responsible for developing and leading the institute’s overall strategic direction. He is one of Canada’s leading scientists and a champion of women in science and young scientists. He chairs, or is a member of, advisory and review boards in Canada, the U.S., U.K., Italy, France and Australia, including the Sabin-Aspen Vaccine Science and Policy Group, the Scientific Advisory Committee of the Bill and Melinda Gates Foundation, and Canada’s COVID-19 Vaccine Task Force. He was appointed Chair of the Federal Variants of Concern Scientific Advisory Council in 2021. Alan Bernstein’s contributions to science and science policy have been recognized with numerous awards and honorary degrees, including Officer of the Order of Canada, the Order of Ontario, the McLaughlin Medal from the Royal Society of Canada, the Award of Excellence from the Genetics Society of Canada, the Gairdner Foundation Wightman Award, induction into the Canadian Medical Hall of Fame, and the 2017 Henry Friesen International Prize in Health Research.
 

Prof. Alexis Brice

Trained in neurology and molecular biology, over the past thirty years Alexis Brice has developed successful research on the clinical aspects, molecular bases and physiopathology of several neurodegenerative diseases, including Parkinson’s disease, cerebellar ataxias, spastic paraplegias and frontotemporal dementia. His team has identified many causative genes, improving diagnosis and genetic counselling as well as providing new physiopathological insights using cellular and animal models of these diseases. His work has led to the publication of more than 700 research articles in the field of neurology and genetics. Professor of medical genetics at Sorbonne University and a neurologist, he has also shown leadership as former head of the Department of Medical Genetics at the Pitié-Salpêtrière University Hospital, as Director of the Institute for Neuroscience, Cognitive Science, Neurology and Psychiatry at the national level, and now as the Executive Director of the largest neuroscience institute in France, the Paris Brain Institute – ICM, devoted to basic, translational and clinical neurosciences.
 

Dr. Rory Collins

Rory Collins is an epidemiologist who studies prevention and treatment of cardiovascular disease in large population-based studies. He trained in medicine at St Thomas’s Hospital, London University, and statistics at George Washington and Oxford universities. He has been at Oxford since 1981, where he is currently Head of the Nuffield Department of Population Health.

During the 1980s and early 1990s, Rory Collins coordinated the ISIS “mega-trials” of the emergency treatment of heart attacks involving more than 130,00 patients. These trials showed that clot-dissolving and clot-preventing treatment could more than halve mortality, rapidly becoming part of routine care worldwide (as well as paving the way for selective use of non-pharmaceutical methods to open coronary arteries).

Since the early 1990s, he has been involved in conducting large-scale randomized trials of the effects of modifying blood levels of cholesterol. For example, the 20,000 patient Heart Protection Study that he led showed that lowering LDL-cholesterol with statin therapy safely reduces the risk of death and disability from cardiovascular disease among a much wider range of people than had been thought likely to benefit. As a consequence, statin therapy is now used extensively worldwide.

He became Principal Investigator of UK Biobank in 2005. Involving 500,000 participants, it is the largest deeply characterized prospective study of disease globally, available for any type of health research. Over 30,000 researchers worldwide use it currently, generating 1,700 papers in 2021 alone.

He was knighted for services to science in 2011, elected to the Royal Society in 2015, and awarded the UK Medical Research Council’s 2020 Millennium Medal for his national and international contributions to both cardiovascular disease and the UK Biobank.
 

Dr. David Gozal

Dr. Gozal is currently the Marie M. and Harry L. Smith Endowed Chair and the Chairman of the Department of Child Health at the University of Missouri, as well as Physician-in-Chief of the University of Missouri Health Children’s Hospital. Dr. Gozal’s research interests include projects such as gene and cellular regulation in hypoxia and sleep disruption, murine models of sleep disorders, and genomic and proteomic approaches to clinical and epidemiological aspects of sleep apnea in both adults and children. In addition, he has pioneered biomarker discovery and machine learning approaches for the diagnosis of sleep apnea across the lifespan. More recently, he has begun exploration of the role of the gut microbiome and circulating exosomes as mechanistic effectors and biomarkers in sleep disorders and associated morbidities.

Dr. Gozal is past president of the American Thoracic Society, the world-leading organization for pulmonary, critical care and sleep medicine. He was a member of the Board of Directors of the Sleep Research Society from 2014 to 2016 and is Deputy Editor-in-Chief for the journal Sleep, as well as Associate Editor for ERJ, Pediatric Pulmonology, Frontiers in Neurology and Frontiers in Psychiatry. He has been the recipient of the ATS Amberson Lecture in 2002 and was awarded the William C. Dement Academic Achievement Award by the American Academy of Sleep Medicine in 2013 and the 2016 Lifetime Achievement Award of the National Sleep Foundation. He has also received two honorary doctorates from the University of Barcelona and University of Lleida in Spain. His research has been continuously supported by grants from the NIH since 1992. He has published over 800 peer-reviewed original articles carrying an H index of 129 and over 70,000 citations (one of the top 2,000 most cited scientists in the world), along with more than 175 book chapters and reviews. He has also edited four books, presented more than 1,000 scientific abstracts, and lectured extensively all over the world.
 

Prof. Glenda Elisabeth Gray

An NRF A1-rated scientist, CEO and President of the South African Medical Research Council (SAMRC), Professor Glenda Gray is a qualified pediatrician and co-founder of the internationally recognized Perinatal HIV Research Unit in Soweto, South Africa. Prior to her appointment at the SAMRC, she was the Executive Director of the Perinatal HIV Research Unit, an affiliate of Wits University.

Glenda Elisabeth Gray’s global profile includes a role as Co-PI of the HIV Vaccine Trials Network (HVTN), a transnational collaboration for the development of HIV/AIDS prevention vaccines. She is also Director of International Programmes for HVTN, Chairperson of the Board of the Global Alliance for Chronic Diseases, and a member of the Institute of Medicine of the National Academies, USA.

She received South Africa’s highest honour ─ the Order of Mapungubwe ─ for her pioneering research in PMTCT. Other prestigious accolades include the Nelson Mandela Health and Human Rights Award for significant contributions in the field of mother-to-child transmission of HIV. Selected as one of Time’s 100 Most Influential People in the World, Glenda is a recognized leader in her field. Her qualifications include an MBBCH, FCPaeds (SA), DSc (honoris causa SFU), DSc (honoris causa SUN), LL.D (Rhodes).
 

Dr. Julie R. Ingelfinger

Julie R. Ingelfinger, MD, is a professor of pediatrics at Harvard Medical School, senior consultant in pediatric nephrology at MassGeneral Hospital for Children at Massachusetts General Hospital, and a deputy editor of the New England Journal of Medicine. She has been a consultative pediatric nephrologist, hypertension specialist and mentor in these areas for several decades. Her commitment to teaching is reflected in the multiple awards she has received. These include the Henry L. Barnett award from the American Academy of Pediatrics (2009), the Founders Award from the American Society of Pediatric Nephrology (2012), the National Kidney Foundation’s Honors Award (2018), and an alumni achievement award from Albert Einstein College of Medicine (2018).

For many years, Dr. Ingelfinger has been involved in studies of the intrarenal renin angiotensin aldosterone system (RAAS), perinatal programming, and the interaction of the coagulation pathways and microvascular disease. Her current projects focus on the role of the intrarenal vasoactive pathways in disease states and the role of maternal nutrition in kidney development and perinatal programming.

Interested in innovative ways to teach writing and communication, Dr. Ingelfinger has been an editor of the textbook Pediatric Hypertension, in each of its 4 editions.
 

Dr. Calum MacRae

Calum MacRae, MD, PhD, is Professor of Medicine at Harvard Medical School, Vice Chair for Innovation in the Department of Medicine at Brigham and Women’s Hospital (BWH), an Associate Member at the Broad Institute of Harvard and MIT and a Principal Faculty Member at the Harvard Stem Cell Institute. He was previously Chief of Cardiovascular Medicine at BWH.

He co-directs the Genomic Medicine Program at BWH, is a member of the Cardiovascular Clinical Genetics Center and is an investigator in the Harvard Undiagnosed Diseases Center. Dr. MacRae is the Director of One Brave Idea, a program to transform translation, initially in atherosclerosis, that is funded jointly by the American Heart Association, Verily Life Sciences and AstraZeneca, with support from Quest Diagnostics. He is also the principal investigator of the Apple Heart & Movement study and directs an NIH-funded basic science group focused on the developmental basis of disease and phenotype-driven drug discovery.
 

Dr. Lillian Siu

Dr. Siu is a senior medical oncologist at Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at Princess Margaret Cancer Centre and holds the BMO Chair in Precision Genomics (2016-2026). She is also the Clinical Lead for the Tumor Immunotherapy Program at Princess Margaret Cancer Centre. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016). She also served as a member of the Nomination Committee for the American Association for Cancer Research (AACR) (2014-2016) and on the AACR Board of Directors for a three-year term (2017-2020).

Dr. Siu’s major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies. She is the Principal Investigator of a phase I cooperative agreement UM1 award sponsored by the United States National Cancer Institute. In addition to her active research in early phase clinical trials, she has been leading genomics initiatives and immuno-oncology trials at the Princess Margaret Cancer Centre. Together, the three programs of drug development, cancer genomics and tumor immunotherapy form a triad of synergy that supports the institution’s core vision to deliver precision cancer medicine.

Internationally, Dr. Siu was the recipient of the U.S. NCI Michaele C. Christian Award in Oncology Drug Development in 2010. She has been awarded the TAT 2020 Honorary Award for contributions in the development of anticancer drugs. Locally, she was awarded the University of Toronto Department of Medicine Eaton Scholar Researcher in 2016. She was the ASCO Conquer Cancer Foundation Grants Selection Committee Chair in 2009-10. She was Chairperson of the AACR Education Committee, Co-Chairperson of the Scientific Committee for the 2012 Annual Meeting and Co-Chairperson for the Clinical Trials Committee 2015-2017. Dr. Siu has published over 370 peer-reviewed manuscripts. She is currently the Editor-in-Chief for AACR’s newest journal, Cancer Research Communications, a scientific editor for Cancer Discovery, and on the editorial board for JAMA Oncology, Cell and Cancer Cell.